Study details
Enrolling now
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation
University of Florida
NCT IDNCT05800210ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
20
Study length
about 3.1 years
Ages
0.5–39
Locations
1 site in FL
About this study
This trial is testing a treatment to deplete alpha/beta T cells and CD19+ B cells from allogeneic stem cell transplants. The goal is to assess the safety, efficacy, and feasibility of this treatment approach for patients with certain types of cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Use Miltenyi CliniMACS Prodigy ® system
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Event-free survival, Overall survival
Devices
therapeutic
Body systems
Oncology